MarketCap
Insmed Incorporated INSM
$ 114.55
5.29%
Facebook
X
Telegram
Insmed Incorporated ROCE Ratio | INSM
Annual ROCE Ratio Insmed Incorporated
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -69.43 | -50.83 | -64.27 | -31.19 | -33.84 | -39.16 | -35.8 | -58.56 | -45.26 | -82.58 | -35.15 | -41.36 | -34.38 | -30.79 | -26.4 | -4.19 | -7.0 | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -4.19 | -82.58 | -40.6 |
Quarterly ROCE Ratio Insmed Incorporated
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -32.32 | -45.67 | -60.01 | -66.94 | -62.47 | -55.54 | -63.57 | -67.41 | -70.22 | -71.41 | -68.02 | -59.45 | -53.64 | -55.44 | -45.77 | -43.37 | -41.97 | -35.72 | -34.15 | -39.14 | -44.15 | -42.94 | -41.82 | -38.07 | -31.28 | -32.19 | -34.15 | -38.03 | -47.58 | -53.15 | -55.21 | -49.86 | -48.8 | -44.13 | -64.61 | -76.39 | -92.67 | -98.11 | -80.4 | -71.06 | -48.88 | -43.91 | -38.04 | -43.28 | -44.45 | -45.68 | -55.81 | -51.96 | -50.79 | -49.76 | -38.83 | -38.16 | -39.91 | -36.42 | -37.26 | -31.23 | -26.29 | -44.44 | -42.66 | -42.55 | -24.55 | -5.92 | -5.52 |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -5.52 | -98.11 | -48.3 |
ROCE Ratio of other stocks in the Biotechnology industry
| Issuer | ROCE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Inozyme Pharma
INZY
|
-179.9 | - | - | $ 207 M |  USA |
 |
Idera Pharmaceuticals
IDRA
|
-235.23 | - | -23.04 % | $ 26.6 M | USA |
 |
NanoString Technologies
NSTG
|
-332.18 | - | -37.43 % | $ 5.1 M | USA |
 |
Humanigen
HGEN
|
146.06 | - | -81.12 % | $ 4.28 M | USA |
 |
Sorrento Therapeutics
SRNE
|
2710.64 | - | -29.58 % | $ 126 M | USA |
 |
Surface Oncology
SURF
|
-66.24 | - | - | $ 59.7 M | USA |
 |
GlaxoSmithKline plc
GSK
|
19.97 | $ 50.28 | -0.27 % | $ 204 B |  Britain |
 |
Sierra Oncology
SRRA
|
-98.53 | - | -0.05 % | $ 1.34 B |  Canada |
 |
Cocrystal Pharma
COCP
|
-120.22 | $ 1.03 | 2.95 % | $ 11.6 M | USA |
 |
Atea Pharmaceuticals
AVIR
|
-65.67 | $ 4.27 | 1.18 % | $ 348 M | USA |
 |
Vaccinex
VCNX
|
753.01 | - | -61.37 % | $ 654 K | USA |
 |
ImmuCell Corporation
ICCC
|
4.28 | $ 9.9 | -0.5 % | $ 89.4 M | USA |
 |
Nymox Pharmaceutical Corporation
NYMX
|
63.22 | - | -19.68 % | $ 18.4 M | Canada |
 |
Akero Therapeutics
AKRO
|
-38.05 | - | - | $ 3.67 B | USA |
 |
Jounce Therapeutics
JNCE
|
-28.53 | - | - | $ 98.4 M | USA |
 |
Immutep Limited
IMMP
|
-29.25 | $ 3.25 | 20.82 % | $ 4.73 B |  Australia |
 |
Verona Pharma plc
VRNA
|
-35.83 | - | - | $ 69.7 B | Britain |
 |
Keros Therapeutics
KROS
|
21.27 | $ 9.32 | -1.43 % | $ 347 M | USA |
 |
Kazia Therapeutics Limited
KZIA
|
-45.76 | $ 7.19 | 2.71 % | $ 110 M | Australia |
 |
Corner Growth Acquisition Corp.
COOL
|
669.98 | - | -0.89 % | $ 114 M | USA |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
2.69 | $ 306.2 | 2.41 % | $ 5.92 B | USA |
 |
Acorda Therapeutics
ACOR
|
167.74 | - | -24.86 % | $ 820 K | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-75.24 | - | -11.43 % | $ 502 K | USA |
 |
Akari Therapeutics, Plc
AKTX
|
-60.98 | $ 7.95 | 2.57 % | $ 535 B | Britain |
 |
Mersana Therapeutics
MRSN
|
-36.18 | - | - | $ 3.56 B | USA |
 |
CymaBay Therapeutics
CBAY
|
-34.79 | - | - | $ 3.45 B | USA |
 |
Freeline Therapeutics Holdings plc
FRLN
|
-187.83 | - | - | $ 384 M | Britain |
 |
Genmab A/S
GMAB
|
31.74 | $ 53.62 | 1.67 % | $ 3.47 B |  Danmark |
 |
Allakos
ALLK
|
-155.07 | - | - | $ 28.6 M | USA |
 |
Timber Pharmaceuticals
TMBR
|
-367.47 | - | - | $ 717 K | USA |
 |
Ionis Pharmaceuticals
IONS
|
-43.85 | $ 39.67 | 2.24 % | $ 6.35 B | USA |
 |
Iovance Biotherapeutics
IOVA
|
-52.06 | $ 8.1 | 4.59 % | $ 2.89 M | USA |
 |
Immuron Limited
IMRN
|
-65.47 | $ 0.82 | -3.68 % | $ 189 M | Australia |
 |
G1 Therapeutics
GTHX
|
-111.7 | - | - | $ 370 M | USA |
 |
Amryt Pharma plc
AMYT
|
-5.86 | - | - | $ 621 M | Britain |
 |
MediWound Ltd.
MDWD
|
-38.77 | $ 14.18 | 6.38 % | $ 386 M |  Israel |
 |
Kinnate Biopharma
KNTE
|
-76.05 | - | - | $ 123 M | USA |
|
Cerevel Therapeutics Holdings
CERE
|
-66.38 | - | - | $ 7.29 B | USA |
 |
Nektar Therapeutics
NKTR
|
-155.96 | $ 37.25 | 3.04 % | $ 628 M | USA |
 |
Immunome
IMNM
|
-35.33 | $ 18.71 | 4.5 % | $ 1.63 B | USA |
 |
NexImmune
NEXI
|
-939.5 | - | 70.13 % | $ 4.12 M | USA |
 |
Kala Pharmaceuticals
KALA
|
-559.76 | $ 0.16 | 2.1 % | $ 1.3 M | USA |
 |
Theravance Biopharma
TBPH
|
6.74 | $ 17.03 | 0.03 % | $ 857 M |  Cayman-islands |
 |
IMV
IMV
|
-79.29 | - | - | $ 13.1 M | Canada |
 |
Karuna Therapeutics
KRTX
|
-39.45 | - | - | $ 12.2 B | USA |
 |
Chimerix
CMRX
|
-79.36 | - | - | $ 756 M | USA |
 |
Atreca
BCEL
|
-34.9 | - | -11.76 % | $ 5.79 M | USA |
 |
LogicBio Therapeutics
LOGC
|
-126.88 | - | - | $ 229 M | USA |
|
89bio
ETNB
|
-95.97 | - | - | $ 1.55 B | USA |
 |
Fusion Pharmaceuticals
FUSN
|
-44.6 | - | - | $ 1.41 B | Canada |